Novo Nordisk A/S (NVO) kicked off 2026 with a major milestone: the U.S. launch of the Wegovy weight-loss pill. This marks the first oral GLP-1 therapy, which was approved by the Food and Drug Administration (FDA) in late December. And this wasn’t just another product rollout. It signaled a strategic shift in the way obesity treatment is delivered.
Where injectable GLP-1 drugs require in-office or self-administered shots, a daily pill dramatically lowers the barrier to treatment for millions of patients who prefer a familiar, convenient option.
